Clinical Study
Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes
Table 3
Clinical response and sustained clinical response of subgroups within the modified intent-to-treat population.
| | Clinical response | Fidaxomicin
number/number (%) | Vancomycin
number/number (%) | Change (%) | Difference (CI) |
| | Age ≥ 65 years | 81/93 (87.1) | 81/92 (88.0) | | −0.9 (−10.5, 8.7) | | Concomitant antibiotic use | 24/27 (88.9) | 21/27 (77.8) | | 11.1 (−9.3, 30.0) | | Cancer | 19/23 (82.6) | 27/31 (87.1) | | −4.5 (−24.4, 14.7) | | Renal dysfunction | 43/56 (76.8) | 48/55 (87.3) | | −10.5 (−24.2, 4.0) | | BI strain | 55/66 (83.3) | 59/67 (88.1) | | −4.7 (−16.6, 7.4) | | Non-BI strain | 93/99 (93.9) | 106/110 (96.4) | | −2.4 (−8.7, 3.8) |
| | Sustained clinical response | Fidaxomicin
number/number (%) | Vancomycin
number/number (%) | Change (%) | value |
| | Age ≥ 65 years | 68/93 (73.1) | 56/92 (60.9) | 20.1 | 0.076 | | Concomitant antibiotic use | 31/43 (72.1) | 19/37 (51.4) | 40.4 | 0.056 | | Cancer | 18/23 (78.3) | 19/31 (61.3) | 27.7 | 0.184 | | Renal dysfunction | 33/56 (58.9) | 30/55 (54.5) | 8.0 | 0.641 | | BI strain | 46/66 (69.7) | 42/67 (62.7) | 11.2 | 0.393 | | Non-BI strain | 82/99 (82.8) | 76/110 (69.1) | 19.9 | 0.021 |
|
|
BI, BI/NAP1/027; CI, confidence interval.
.
|
